Retatrutide Post-Cycle Weight Rebound: STEP Withdrawal Research and UAE Maintenance Dosing (2026)

Why Post-GLP-1 Rebound Is the Most Important Research Question of 2026

Every paper that built the GLP-1 / GIP / glucagon obesity story — STEP 1, SURMOUNT-1, Jastreboff 2023 — measured outcomes while subjects kept dosing. The hidden second chapter is what happens when the drug stops. For UAE researchers running 24 to 48-week retatrutide protocols, this rebound chapter is the difference between a sustained outcome and an expensive round-trip.

The STEP 1 trial extension by Wilding and colleagues was the first large, well-controlled look at what happens after a long GLP-1 cycle ends. The pattern that emerged there is now informing how serious researchers — including those buying retatrutide UAE 24h delivery Dubai — design their off-cycle phase.

The Wilding 2022 STEP Withdrawal Extension — What Actually Happened

STEP 1 ran semaglutide 2.4 mg weekly for 68 weeks against placebo. The withdrawal extension followed 327 participants for an additional 52 weeks after they discontinued semaglutide and lifestyle support. Key findings:

• Mean weight loss at week 68 (end of treatment): 17.3% from baseline.
• By week 120 (52 weeks post-discontinuation): participants had regained roughly two-thirds of lost weight, ending at approximately 5.6% below baseline.
• Cardiometabolic improvements — waist circumference, HbA1c, lipids, blood pressure — also reverted toward baseline in parallel with weight.
• The regain trajectory was steepest in the first 20 weeks off-drug, then flattened.

This is not "the drug failed." This is exactly what physiology predicts: semaglutide produced a new appetite set-point while it was occupying the GLP-1 receptor; removing the ligand returned signalling to baseline. Retatrutide, hitting three receptors instead of one, almost certainly behaves the same way — only with a larger absolute peak to fall from.

The Mechanistic Picture — Why Rebound Is Predictable

Ghrelin compensation

GLP-1 agonism suppresses appetite both centrally (hypothalamic POMC neurons) and peripherally (slowed gastric emptying). When the drug clears, gastric emptying speeds back up within days; ghrelin (the "hunger" hormone) returns to or above pre-treatment levels within 4 to 8 weeks. The brain interprets this as a famine signal — exactly the same response that defeats every low-calorie diet.

Adipose set-point

Body weight is defended around a learned set-point. GLP-1 / GIP / glucagon agonists lower the defended weight temporarily; remove the agonist and the hypothalamus drives intake upward until the prior set-point is recovered. Retatrutide's glucagon arm adds a thermogenic / energy-expenditure component that also reverses on cessation.

Reward signalling

GLP-1 receptors in the ventral tegmental area dampen food reward. Off-drug, the dopaminergic response to palatable food returns within weeks. This is the subjective "food got loud again" report common in semaglutide and retatrutide users post-cycle.

Projected Retatrutide Rebound Timeline

The table below extrapolates from Wilding 2022 STEP withdrawal data and applies the scaling factor from the Jastreboff 2023 retatrutide phase 2 trial (which produced 24.2% weight loss at 12 mg vs STEP 1's 17.3% at 2.4 mg semaglutide). It is a projection, not a published retatrutide-specific dataset — that withdrawal extension trial has not yet read out.

The takeaway is timing: weeks 5 to 16 post-cessation are the critical window. A maintenance dose introduced or held during this window flattens the curve. Waiting until rebound is established and then re-titrating is harder — it means escalating through hunger that has already returned.

Maintenance Dosing Strategy — Three Protocols

Option A — Reduced weekly dose

• Step down from peak (e.g. 12 mg) to 2 to 4 mg weekly SC.
• Maintains receptor occupancy across all three targets.
• Side-effect burden drops with dose.
• Commonly used for: researchers who want the simplest schedule.

Option B — Extended interval

• Hold peak or near-peak dose, extend interval to every 10 to 14 days.
• Exploits retatrutide's ~6-day half-life — receptor occupancy stays above threshold longer than semaglutide allows.
• Useful if cost or vial economy matters.

Option C — Pulsed cycles

• 4 to 8 weeks on at low dose (1 to 2 mg), 2 to 4 weeks off.
• Less data behind this; primarily a tolerability strategy.
• Risk: each "off" phase risks a small rebound that accumulates.

For most UAE research protocols, Option A is the cleanest starting point. Detailed titration steps for the on-cycle phase are in our retatrutide titration schedule UAE guide.

Behavioural Anchors That Protect the Loss

Pharmacology buys time; behaviour decides whether the new lower set-point holds. The post-cycle window is the right time to lock in:

1. Resistance training 3x weekly. Preserves lean mass that defends a lower body weight via resting metabolic rate.
2. Protein floor 1.6 to 2.2 g/kg. Supports satiety and lean-mass preservation; matters more once ghrelin returns.
3. Sleep regularity. Short sleep raises ghrelin and lowers leptin — the exact hormonal direction the rebound is already pushing.
4. Weigh-ins at fixed cadence. Detect a 2 kg drift before it becomes a 10 kg drift; trigger a maintenance dose reinstatement decision early.
5. Pair with adjuncts during off-phase if appropriate. Some researchers stack MOTS-c or other metabolic peptides for the bridge.

UAE Delivery & Sourcing — Buy Retatrutide UAE Same Day

REVIVE LAB operates from Dubai with cold-chain courier coverage across the seven emirates. Practical sourcing notes for UAE researchers planning a peak + maintenance protocol:

• Retatrutide in stock UAE — 5 mg and 10 mg vials held in Dubai temperature-controlled storage.
• 24h delivery emirates — Dubai, Abu Dhabi, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, Fujairah.
• Same-day Dubai metro — orders placed before 4 PM dispatched the same business day.
• Cold-chain — insulated cooler with phase-change gel packs; vials remain 2–8 °C from despatch to door.
• HPLC certificate of analysis included with every batch; purity targets above 99%.
• Bundle with bacteriostatic water — 3 mL BAC water vials available so researchers can reconstitute on arrival.
• Maintenance-phase pricing — buying a 10 mg vial for the maintenance phase delivers ~30% lower per-mg cost vs two 5 mg vials.

Order via the retatrutide UAE product page for current pricing and the live in-stock indicator. The full REVIVE UAE peptide catalogue is searchable by goal and emirate delivery window.

Common Post-Cycle Mistakes UAE Researchers Make

1. Hard stop at peak dose. Going from 12 mg directly to 0 mg produces the steepest rebound curve. Step down through 8 → 4 → 2 mg over 4 to 8 weeks instead.
2. Waiting for full rebound before restarting. Re-titrating from zero through hunger that has already returned takes longer and is harder to tolerate than a planned maintenance dose.
3. Ignoring resting heart rate trends. The HR elevation on retatrutide reverses off-drug — useful baseline data, but not a signal to push higher on the next cycle.
4. Letting vials expire during the off-phase. Reconstituted retatrutide is stable ~28 days refrigerated. For a planned restart at week 8, time the new order to arrive fresh — REVIVE's 24h Dubai dispatch makes just-in-time ordering practical.
5. Skipping body-composition tracking. Weight regain that is mostly fat is a different signal than regain that includes lean mass. DEXA or bio-impedance reads matter more post-cycle than during.

How Retatrutide Rebound Compares to Other GLP-1 Agents

The pattern is consistent: deeper loss means a larger absolute regain in pounds or kilograms, but the fraction regained sits near two-thirds across agents. Whichever GLP-1 family agent you research, a maintenance plan is the difference between holding most of the loss and round-tripping back.

Related Internal Reading

For the on-cycle phase, see our retatrutide titration schedule for UAE researchers and the semaglutide vs retatrutide UAE comparison. To order, the retatrutide UAE 24h delivery page is the canonical buying route.